Cancer Diagnostics Market

The Cancer Diagnostics market is projected to reach USD 44.92 billion by 2031 from USD 29.86 billion in 2026, growing at a CAGR of 7.0%.

Cancer diagnostics play a vital role in oncology by enabling early detection, accurate diagnosis, disease characterization, treatment selection, and monitoring of cancer. The Cancer Diagnostics Market, by Product, comprises a comprehensive portfolio of instruments and consumables across IVD testing, anatomic pathology, and imaging-based diagnostics. The product segment is primarily driven by the increasing adoption of advanced diagnostic instruments and the recurring demand for consumables, supported by the rising global cancer burden, expanding cancer screening programs, and increasing diagnostic testing volumes.

To know about the assumptions considered for the study download the pdf brochure

The market includes diagnostic technologies such as PCR, immunohistochemistry (IHC), in situ hybridization (ISH), next-generation sequencing (NGS), microarrays, flow cytometry, immunoassays, histopathology, cytopathology, biopsy, CT, MRI, PET, mammography, and ultrasound. These products are used for the diagnosis of solid tumors and hematological malignancies and support applications including screening & early detection, diagnosis & disease characterization, treatment decision support, and monitoring & recurrence detection.

This report segments the Cancer Diagnostics market by product, type, application, technology, end user, and region.

Prominent players in the global Cancer diagnostics market include Prominent players in the global cancer diagnostics market include Roche Diagnostics (Switzerland), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Agilent Technologies, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Hologic, Inc. (US), Becton, Dickinson and Company (US), Exact Sciences Corporation (US), Guardant Health, Inc. (US), Sysmex Corporation (Japan), Foundation Medicine, Inc. (US), Myriad Genetics, Inc. (US), NeoGenomics Laboratories, Inc. (US), bioMérieux SA (France), and Revvity, Inc. (US).

Roche Diagnostics (Switzerland)

Roche Diagnostics' leadership in the cancer diagnostics market is driven by its comprehensive portfolio spanning tissue diagnostics, molecular diagnostics, companion diagnostics, and digital pathology. The company offers industry-leading oncology solutions through its VENTANA immunohistochemistry and in situ hybridization platforms, Cobas molecular testing systems, and navify digital pathology solutions. Roche further strengthens its position through Foundation Medicine, enabling comprehensive genomic profiling and precision oncology. Its extensive global installed base, strategic pharmaceutical partnerships for companion diagnostics, continuous investment in biomarker development, and strong presence across hospitals, pathology laboratories, and cancer centers reinforce its position as the global leader in cancer diagnostics.

Danaher Corporation (US)

Danaher's leadership in the cancer diagnostics market is supported by its diversified oncology portfolio across Leica Biosystems, Cepheid, Beckman Coulter Diagnostics, and Integrated DNA Technologies (IDT). The company provides advanced pathology solutions, molecular diagnostics, PCR-based oncology assays, flow cytometry, hematology, and laboratory automation systems that support cancer detection and precision medicine. Leica Biosystems is a global leader in tissue diagnostics and digital pathology, while Cepheid delivers rapid molecular testing platforms. Combined with its strong global commercial network, continuous innovation, and strategic acquisitions, Danaher maintains a leading position across pathology laboratories, hospital laboratories, academic research institutions, and cancer centers worldwide.F. Hoffmann-La Roche Ltd. (Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific's leadership in the cancer diagnostics market is driven by its broad portfolio of molecular diagnostics, next-generation sequencing (NGS), PCR technologies, pathology solutions, and companion diagnostics. The company's oncology portfolio includes Ion Torrent sequencing systems, Oncomine precision oncology assays, qPCR platforms, pathology antibodies, FISH probes, and bioinformatics solutions supporting comprehensive genomic profiling and biomarker testing. Thermo Fisher serves pharmaceutical companies, clinical laboratories, hospitals, and research institutions through an integrated workflow covering sample preparation, sequencing, analysis, and reporting. Continuous investment in precision medicine, companion diagnostic partnerships, and global commercial expansion further strengthens its position as one of the leading players in the global cancer diagnostics market.Switzerland).

Market Ranking

The cancer diagnostics market is moderately consolidated, with the top ten players accounting for approximately 70–75% of the global market in 2025. Leading companies include Roche Diagnostics (Switzerland), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), Siemens Healthineers AG (Germany), Agilent Technologies, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Hologic, Inc. (US), and Becton, Dickinson and Company (US). These companies maintain their leadership through comprehensive oncology diagnostic portfolios, strong global commercial presence, and continuous investments in precision medicine and advanced diagnostic technologies.

The market presents significant growth opportunities across North America, Europe, and Asia Pacific, particularly in China, India, Japan and South Korea driven by increasing cancer incidence, expanding national cancer screening programs, improving healthcare infrastructure, and growing investments in precision oncology. Rising adoption of companion diagnostics, biomarker-based testing, and genomic profiling is further accelerating market expansion across both developed and emerging economies.

The increasing global burden of cancer, aging populations, growing awareness of early cancer detection, and rising demand for personalized treatment approaches continue to drive the adoption of advanced cancer diagnostics across hospitals, diagnostic laboratories, pathology laboratories, cancer centers, and reference laboratories. Government initiatives supporting population-based screening, favorable reimbursement policies in developed markets, and increasing investments in oncology research are further strengthening market growth.

Technological advancements in molecular diagnostics, next-generation sequencing (NGS), digital pathology, liquid biopsy, multiplex biomarker testing, companion diagnostics, artificial intelligence (AI)-enabled image analysis, laboratory automation, and integrated bioinformatics platforms are transforming cancer diagnosis by enabling earlier detection, improved diagnostic accuracy, and personalized treatment selection. Companies are increasingly focusing on integrated oncology workflows, precision medicine solutions, and strategic collaborations with pharmaceutical and biotechnology companies to strengthen their competitive positioning and support the growing demand for precision oncology worldwide.

Related Reports:

Cancer Diagnostics Market by Product (Consumables (Antibodies, Probes), Instruments), Technology (IVD Testing, Anatomic pathology, Imaging, Biopsy), Type (Tumors, Breast, Lung Cancer), Application, End User (Hospitals) & Region – Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]